Reata Pharmaceuticals EBIT

Reata Pharmaceuticals (RETA) currently reports a EBIT of $-340M as of June 2023. That compares with $-260M in the prior-year period — down 32.6% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Reata Pharmaceuticals's EBIT history and peer comparisons.

Reata Pharmaceuticals's EBIT decreased from $-260M to $-340M — a 32.6% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reata Pharmaceuticals's EBIT of $-340M is lower than the Healthcare sector average of $23B. That is roughly 101.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Reata Pharmaceuticals reported $-340M in EBIT as of June 2023. That compares with $-260M in the prior-year period — down 32.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-340M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Reata Pharmaceuticals, and consider following RETA for alerts when major investors trade the stock.